| Mountain State Medical Policy Bulletin |
| Section: | Surgery |
| Number: | S-75 |
| Topic: | Extracorporeal Photopheresis |
| Effective Date: | August 1, 2005 |
| Issued Date: | August 1, 2005 |
| Date Last Reviewed: | 06/2005 |
Indications and Limitations of Coverage
Extracorporeal photopheresis is eligible for payment. A cycle of extracorporeal photopheresis consists of treatment on two consecutive days, once a month. If there is no response to the treatment within six to eight months, the treatment is stopped. Each day of the two-day cycle should be processed and paid under code 36522. Description Extracorporeal photopheresis (code 36522) is a treatment primarily for cutaneous T-cell lymphoma (CTCL), a condition that is generally resistant to chemotherapy and radiotherapy. The treatment begins with oral administration of the drug, Methoxsalen. The patient's blood is then passed through a device that permits exposure of the blood, while it is outside the body (extra-corporeal), to ultraviolet A light. The blood is then returned to the patient. Patients generally receive photopheresis treatment on two consecutive days. |
| 36522 |